Changes in progenitor cell population in breast may be overlooked factor in breast cancer
Research presented at the American Society for Cell Biology (ASCB) annual meeting, 15-19 December 2012, San Francisco.
Research presented at the American Society for Cell Biology (ASCB) annual meeting, 15-19 December 2012, San Francisco.
by Bruce Sylvester – FDA Highlights – Treatment with denosumab decreases the number of tumor giant cells in patients with giant-cell tumor of the bone, and increases new… read more.
by Bruce Sylvester – taken from The Lancet – Radiotherapy given immediately after prostate removal surgery has a long-term benefit of preventing progression of the disease, researchers reported… read more.
by Bruce Sylvester – taken from the Journal of the American Medical Association (JAMA) – Researchers comparing methods for treating low-grade gliomas have found early surgical resection produced… read more.
by Bruce Sylvester – taken from the New England Journal of Medicine (NEJM) – Aspirin therapy appears to extend life in colorectal cancer patients with tumors having a… read more.
by Marybeth Burke – Initial combination chemotherapy with bendamustine and rituximab more than doubled progression-free survival to nearly 6 years compared with standard R-CHOP therapy among patients with… read more.
by Marybeth Burke – Adding bevacizumab to chemotherapy halves the risk of the disease getting worse in platinum resistant patients with ovarian cancer,
by Marybeth Burke – Crizotinib demonstrated significant anti-tumour activity in patients with advanced non-small cell lung cancer (NSCLC) harbouring ROS1 rearrangements,
by Marybeth Burke – Women treated for childhood cancer with chest radiation therapy have a high risk of developing breast cancer at a young age, comparable to that… read more.
by Marybeth Burke – Regorafenib significantly improved progression-free survival (PFS) and disease control rate (DCR) in patients with advanced gastrointestinal stromal tumours (GIST) that progress due to resistance… read more.
by Marybeth Burke – The investigational agent trastuzumab emtansine (T-DM1) demonstrated improved efficacy over capecitibine plus lapatinib and improved progression-free survival (PFS) in women with HER2-positive locally advanced… read more.
by Marybeth Burke – Median progression-free survival (PFS) was significantly greater in the trametinib group, 4.8 months, vs the chemotherapy group, 1.4 months, according to a study presented
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.